14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HNGE vs LCAP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Hinge Health, Inc. (HNGE) is the stronger overall head-to-head candidate over Principal Capital Appreciation Select ETF (LCAP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HNGE carries a Unified Composite Score of 38.4/100 (SELL) at $121.29 (37.2x Forward P/E, 18.8% operating margin), whereas LCAP carries 53.9/100 (HOLD) at $32.67 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While LCAP currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. HNGE 38.4/100 SELL), HNGE captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (18.8% vs. N/A operating margin) and revenue trajectory (+52.4% vs. N/A YoY).
Technical & Structure Timing Caution: HNGE trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8); meanwhile LCAP is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HNGE vs LCAP. Trailing 12-month operating profitability (HNGE 18.8% vs LCAP N/A) and valuation multiples (HNGE 37.2x vs LCAP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Services-Computer Processing & Data Preparation Operator
Competes within the Services-Computer Processing & Data Preparation value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HNGE vs LCAP Key Questions & Quantitative Answers
As of Nov 16, 2026, Hinge Health, Inc. (HNGE) is the stronger overall head-to-head candidate over Principal Capital Appreciation Select ETF (LCAP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HNGE carries a Unified Composite Score of 38.4/100 (SELL) at $121.29 (37.2x Forward P/E, 18.8% operating margin), whereas LCAP carries 53.9/100 (HOLD) at $32.67 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While LCAP currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. HNGE 38.4/100 SELL), HNGE captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (18.8% vs. N/A operating margin) and revenue trajectory (+52.4% vs. N/A YoY). Technical & Structure Timing Caution: HNGE trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8); meanwhile LCAP is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HNGE leads the Growth & Scale pillar: HNGE posts +52.4% YoY revenue growth and -68.4% YoY earnings growth on $1.43B TTM revenue (85.8% gross margin, 18.8% operating margin), compared with LCAP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HNGE generates $1.43B in USD-normalized revenue versus N/A for LCAP. In operating R&D and SG&A reinvestment, HNGE deploys 67.0% of Rev ($956M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCAP.
HNGE screens cheaper on headline valuation multiples. HNGE trades at 37.2x Forward P/E, 31.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (39.4% FCF margin), whereas LCAP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HNGE (47.6% ROE) versus LCAP (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, HNGE carries 61.9% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.14β · 42% Vol realized risk). By comparison, LCAP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.93β · 21% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.